SQLite Web: event_store.db

Update row sig_6d32e072e332 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","company":"Wave Life Sciences Ltd.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1bc54a8ec66c6f35","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:13:13.398667+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt","source_event_id":"evt_0ad86f7f45a3","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"02069f452bbbe4f0","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-16","2026-04-15T02:08:52.472606+00:00","2025-06-23"],"entities":[{"asset_class":"equity","name":"Wave Life Sciences Ltd.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Wave-Singapore","relevance":"high","symbol":"","type":"corporate entity"},{"asset_class":"equity","name":"Wave-Delaware","relevance":"high","symbol":"","type":"corporate entity"},{"asset_class":"other","name":"High Court of the Republic of Singapore","relevance":"medium","symbol":"","type":"court"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["The provided text is a cleaned excerpt that appears to describe a Form 8-K and the redomiciliation; it does not include the specific DEFA14A contents beyond the signal metadata (filed DEFA14A).","What specifically changed vs prior known state is not provided in the text (no prior filing comparison is included).","No financial implications, costs, or expected timing beyond court/shareholder approvals are stated in the provided excerpt.","The excerpt truncates near the end (\u201cWave-Singapore\u2019s Ordi...\u201d), so any additional details in the original document are missing."],"key_facts":["Form DEFA14A was filed in connection with Wave Life Sciences Ltd.\u2019s redomiciliation plan.","On April 15, 2026, Wave Life Sciences Ltd. announced it decided to restructure its corporate group so the parent company becomes a Delaware corporation (the \u201cRedomiciliation\u201d).","Boards of directors of Wave-Singapore and Wave-Delaware approved entry into an Implementation Agreement executed on April 15, 2026.","The Implementation Agreement provides for a Singapore-law scheme of arrangement subject to approval of Wave-Singapore shareholders and the High Court of the Republic of Singapore.","Under the Scheme of Arrangement, all issued Wave-Singapore ordinary shares immediately prior to the effective time will be exchanged on a one-for-one basis for newly issued shares of Wave-Delaware common stock.","Wave-Singapore will become a subsidiary of Wave-Delaware upon completion of the Scheme of Arrangement.","Wave-Singapore expects to file a preliminary proxy statement on Schedule 14A on April 15, 2026 and a definitive proxy statement will be mailed or otherwise disseminated to shareholders.","The Implementation Agreement is referenced as being filed as Exhibit 2.1 to the described current report on Form 8-K (text provided)."],"numeric_claims":[{"label":"share exchange ratio","value":"one-for-one"},{"label":"execution date of Implementation Agreement","value":"2026-04-15"},{"label":"earliest event reported date","value":"2026-04-15"}],"primary_claim":"Wave Life Sciences Ltd. announced and is proceeding with a redomiciliation that will exchange Wave-Singapore ordinary shares for one-for-one newly issued Wave-Delaware common stock via a Singapore scheme of arrangement, subject to shareholder and High Court approvals.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Wave Life Sciences Ltd. filed a DEFA14A related to its planned corporate redomiciliation from Singapore to Delaware. The filing references a scheme of arrangement and a forthcoming preliminary proxy statement on Schedule 14A for shareholder and court approvals.","topics":["SEC filing","DEFA14A","redomiciliation","scheme of arrangement","proxy statement","share exchange","corporate restructuring"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Wave Life Sciences Ltd. \u00b7 Filed 20260415","ticker":"WVE","tickers":["WVE"],"title":"WVE filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-157014.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel